Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions

Eli Lilly and Company (NYSE: LLY) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia’s intranasal glucagon. This is a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia (read more)

Agile MV would like to congratulate the team at Locemia for this important